Source: Office of Cancer Clinical Proteomics Research
The purpose of this notice is to notify the community that the National Cancer Institute's (NCI’s) Office of Cancer Clinical Proteomics Research (OCCPR) is seeking sources to establish a Biospecimen Core Resource (BCR), capable of receiving, qualifying, processing, and distributing annotated biospecimens.
A goal of the next phase of NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is to improve our understanding of cancer biology by extending CPTAC’s scientific approach to additional cancer types where unanswered questions remain on their proteogenomic complexity. A component of this goal is the acquisition of high‐quality, clinically annotated, primary, and untreated tumor specimens from patients with specific cancer types. Tissue Source Sites (TSS) will prospectively collect primary, human tumors according to a SOP-driven protocol optimized for proteomics. Complete cases will consist of tumor, blood, and, where possible, non-malignant tissue.
To Learn More:
If you are interested in learning more about this new sub contract opportunity (Solicitation N02CO57019-02), please visit the following website or contact:
Mandie White, NCI Office of Acquisitions, at email@example.com
The Biospecimen Core Resource (BCR) serves as a biospecimen processing center as outlined in the Statement of Work (SOW) for the Clinical Proteomic Tumor Analysis Consortium (CPTAC). CPTAC is a collaborative effort led by the National Cancer Institute to accelerate our understanding of the molecular basis of cancer through the application of proteome analysis technologies, in order to better understand the proteogenomic complexity of cancer not fully elucidated through genomics.
The Antibody Portal serves as a public resource of well-characterized monoclonal antibodies made available by the NCI for the scientific community.